Analysts’ Viewpoint
Rise in incidence and mortality rate of ovarian cancer is one of the key factors that is driving the global ovarian cancer treatment market value. Increase in awareness about the cancer and growth in screening programs are also fueling market expansion. Researchers and pharmaceutical companies are focusing on developing targeted therapies that address specific molecular abnormalities in ovarian cancer cells. These targeted therapies are aimed at improving treatment efficacy, while minimizing adverse effects on healthy cells.
Key ovarian cancer treatment drug manufacturers are developing immune checkpoint inhibitors and adoptive cell transfer therapies to enhance the immune system's ability to recognize and eliminate cancer cells. The latest ovarian cancer treatment market trends indicate significant investments in development of innovative therapies and diagnostic tools for ovarian cancer by pharmaceutical companies and research institutions.
Ovarian cancer is a cell growth that occurs in ovaries. The cells multiply rapidly and have the ability to invade and destroy healthy body tissues. The risk of ovarian cancer rises with age. It is most commonly diagnosed in the elderly. Changes in genes inherited from parents cause a small percentage of ovarian cancers. BRCA1 and BRCA2 are two genes that increase the risk of ovarian cancer. These genes are also linked to an increase in risk of breast cancer.
Several other gene changes have been linked to the growth in risk of ovarian cancer, including those linked to the Lynch syndrome and the genes BRIP1, RAD51C, and RAD51D. Ovarian cancer can be difficult to detect, as symptoms often appear later in disease progression. Ovarian cancer is treated through surgery, chemotherapy, and other cancer treatments.
Increase in awareness about ovarian cancer and growth in screening programs play a crucial role in driving the ovarian cancer treatment market size. Rise in awareness about ovarian cancer symptoms, risk factors, and the importance of early detection can lead to more cases being diagnosed at an earlier stage when treatment options are more effective.
Awareness initiatives help educate women about the signs and symptoms of ovarian cancer such as abdominal bloating, pelvic pain, changes in bowel or bladder habits, and feeling full quickly. Chances of detecting ovarian cancer at an early stage rise when women recognize these symptoms and seek medical attention promptly. Early detection enables more treatment options and potentially better outcomes.
With early detection, ovarian cancer patients have a wider range of treatment options available. These options may include surgery, chemotherapy, targeted therapy, and immunotherapy. Early-stage ovarian cancer may be treated with less aggressive interventions, preserving fertility and improving quality of life.
Strategic collaborations between ovarian cancer research organizations and companies can be instrumental in advancing the understanding, treatment, and management of ovarian cancer. These collaborations leverage the expertise, resources, and capabilities of both sectors to drive progress in various areas.
Collaborations between research organizations and companies foster joint research efforts focused on understanding the biology of ovarian cancer, identifying novel therapeutic targets, and developing innovative treatment approaches. By combining the knowledge and resources of both sectors, these collaborations can expedite the development of new drugs, immunotherapies, targeted therapies, and other treatment modalities.
In July 2017, Merck and AstraZeneca established a strategic partnership in oncology. Separately, AstraZeneca and Merck will develop and market Lynparza and a prospective medication called Selumetinib in conjunction with their respective PD-L1/PD-1 immuno-oncology drugs, Imfinzi and Keytruda.
According to the ovarian cancer treatment market analysis, the targeted therapy treatment segment accounted for major share in 2022. Targeted therapies are increasingly preferred due to their ability to specifically identify and attack cancer cells while causing less harm to normal cells.
Targeted therapies are often focused on blocking specific molecules or pathways that play a crucial role in the growth and spread of ovarian cancer cells. Examples of targeted therapies include PARP inhibitors, anti-angiogenic agents, and other drugs targeting specific genetic mutations or pathways implicated in ovarian cancer development.
Immunotherapy has also emerged as a promising approach in the treatment of ovarian cancer. Strategies such as development of immune checkpoint inhibitors, which help the immune system recognize and attack cancer cells more effectively, are being studied extensively.
Efforts are also being made to develop personalized cancer vaccines and adoptive cell transfer therapies to harness the patient's immune system in fighting cancer cells. This is providing lucrative ovarian cancer treatment market opportunities to pharmaceutical companies.
As per the latest ovarian cancer treatment market segmentation, the hospitals end-user segment holds significant share of the global industry. Ovarian cancer is a complex disease that often requires a multidisciplinary approach involving various healthcare professionals, specialized facilities, and advanced medical technologies.
Hospitals play a key role in diagnosis, treatment, and management of ovarian cancer, offering comprehensive care and access to a range of treatment modalities. Several hospitals actively engage in clinical research and trials focused on improving ovarian cancer treatment outcomes. This involvement in research and development enables hospitals to stay at the forefront of innovative treatment strategies. This fosters collaborations with pharmaceutical companies and research institutions, thereby contributing to advancements in ovarian cancer treatment.
North America held the largest ovarian cancer treatment market share in 2022. It was closely followed by Europe. Both these regions have demonstrated significant market progress in terms of development and adoption of advanced treatment modalities. They also possess a robust healthcare infrastructure that is conducive to oncology research and innovation.
North America has advanced healthcare systems, including well-established hospitals, research institutions, and cancer centers, equipped with the latest technologies and treatment options. This infrastructure facilitates the delivery of comprehensive care and supports the development of cutting-edge therapies for ovarian cancer.
Rise in incidence and prevalence of ovarian cancer in the U.S. is anticipated to bolster market statistics in North America. According to the American Cancer Society, approximately 19,710 new cases of ovarian cancer have been diagnosed in the U.S. in 2023 so far, with 13,270 women dying from the disease.
The global landscape is fragmented, with the presence of several key players. Leading market players are engaging in strategies such as product portfolio expansion and mergers and acquisitions to increase their global footprint.
AstraZeneca PLC, Roche Holding AG, Bristol-Myers Squibb Company, Merck & Co., Inc., Pfizer Inc., AbbVie Inc., GlaxoSmithKline plc, Novartis AG, and Takeda Pharmaceutical Company Limited are some of the prominent companies operating in the global industry.
These companies have been summarized in the ovarian cancer treatment market report based on parameters such as company overview, product portfolio, financial overview, business segments, business strategies, and recent developments.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 5.1 Bn |
| Market Forecast Value in 2031 | More than US$ 18.3 Bn |
| Growth Rate (CAGR) | 15.4% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis consists of drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 5.1 Bn in 2022
It is projected to reach more than US$ 18.3 Bn by 2031
The CAGR is anticipated to be 15.4% from 2023 to 2031
Increase in incidence and mortality rate of ovarian cancer and advancements in immunotherapy
Europe is expected to account for significant share during the forecast period
AstraZeneca PLC, Roche Holding AG, Bristol-Myers Squibb Company, Merck & Co., Inc., Pfizer Inc., AbbVie Inc., GlaxoSmithKline plc, Novartis AG, and Takeda Pharmaceutical Company Limited
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Ovarian Cancer Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Ovarian Cancer Treatment Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Disease Prevalence & Incidence Rate Overview
5.3. Insights on Immunotherapy in Ovarian Cancer
5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short/Mid/Long Term Impact)
6. Global Ovarian Cancer Treatment Market Analysis and Forecast, by Treatment
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value & Volume Forecast, by Treatment, 2017–2031
6.3.1. Chemotherapy
6.3.2. Targeted Therapy/Immunotherapy
6.3.3. Surgery
6.3.4. Others
6.4. Market Attractiveness Analysis, by Treatment
7. Global Ovarian Cancer Treatment Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by End-user, 2017–2031
7.3.1. Hospitals
7.3.2. Specialty Clinics
7.3.3. Cancer Hospitals/Centers
7.4. Market Attractiveness Analysis, by End-user
8. Global Ovarian Cancer Treatment Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America (LATAM)
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Ovarian Cancer Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value & Volume Forecast, by Treatment, 2017–2031
9.2.1. Chemotherapy
9.2.2. Targeted Therapy/Immunotherapy
9.2.3. Surgery
9.2.4. Others
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Hospitals
9.3.2. Specialty Clinics
9.3.3. Cancer Hospitals/Centers
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Treatment
9.5.2. By End-user
9.5.3. By Country
10. Europe Ovarian Cancer Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value & Volume Forecast, by Treatment, 2017–2031
10.2.1. Chemotherapy
10.2.2. Targeted Therapy/Immunotherapy
10.2.3. Surgery
10.2.4. Others
10.3. Market Value Forecast, by End-user, 2017–2031
10.3.1. Hospitals
10.3.2. Specialty Clinics
10.3.3. Cancer Hospitals/Centers
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Treatment
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific Ovarian Cancer Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value & Volume Forecast, by Treatment, 2017–2031
11.2.1. Chemotherapy
11.2.2. Targeted Therapy/Immunotherapy
11.2.3. Surgery
11.2.4. Others
11.3. Market Value Forecast, by End-user, 2017–2031
11.3.1. Hospitals
11.3.2. Specialty Clinics
11.3.3. Cancer Hospitals/Centers
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Treatment
11.5.2. By End-user
11.5.3. By Country/Sub-region
12. Latin America (LATAM) Ovarian Cancer Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value & Volume Forecast, by Treatment, 2017–2031
12.2.1. Chemotherapy
12.2.2. Targeted Therapy/Immunotherapy
12.2.3. Surgery
12.2.4. Others
12.3. Market Value Forecast, by End-user, 2017–2031
12.3.1. Hospitals
12.3.2. Specialty Clinics
12.3.3. Cancer Hospitals/Centers
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of LATAM
12.5. Market Attractiveness Analysis
12.5.1. By Treatment
12.5.2. By End-user
12.5.3. By Country/Sub-region
13. Middle East & Africa Ovarian Cancer Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value & Volume Forecast, by Treatment, 2017–2031
13.2.1. Chemotherapy
13.2.2. Targeted Therapy/Immunotherapy
13.2.3. Surgery
13.2.4. Others
13.3. Market Value Forecast, by End-user, 2017–2031
13.3.1. Hospitals
13.3.2. Specialty Clinics
13.3.3. Cancer Hospitals/Centers
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Treatment
13.5.2. By End-user
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. AstraZeneca PLC
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Roche Holding AG
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Bristol-Myers Squibb Company
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Merck & Co., Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Pfizer Inc.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. AbbVie Inc.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. GlaxoSmithKline plc
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Novartis AG
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. Financial Overview
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. Takeda Pharmaceutical Company Limited
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. Financial Overview
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. Other Prominent Players
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. Financial Overview
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview
List of Tables
Table 01: Global Ovarian Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 02: Global Ovarian Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 03: Global Ovarian Cancer Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 04: North America Ovarian Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 05: North America Ovarian Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 06: North America Ovarian Cancer Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 07: Europe Ovarian Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 08: Europe Ovarian Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 09: Europe Ovarian Cancer Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Asia Pacific Ovarian Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 11: Asia Pacific Ovarian Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 12: Asia Pacific Ovarian Cancer Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 13: Latin America Ovarian Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 14: Latin America Ovarian Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 15: Latin America Ovarian Cancer Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 16: Middle East & Africa Ovarian Cancer Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 17: Middle East & Africa Ovarian Cancer Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 18: Middle East & Africa Ovarian Cancer Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
List of Figures
Figure 01: Global Ovarian Cancer Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Ovarian Cancer Treatment Market Value Share Analysis, by Treatment, 2022 and 2031
Figure 03: Global Ovarian Cancer Treatment Market Attractiveness Analysis, by Treatment, 2023–2031
Figure 04: Global Ovarian Cancer Treatment Market Value Share Analysis, by End-user, 2022 and 2031
Figure 05: Global Ovarian Cancer Treatment Market Attractiveness Analysis, by End-user, 2023–2031
Figure 06: Global Ovarian Cancer Treatment Market Value Share Analysis, by Region, 2022 and 2031
Figure 07: Global Ovarian Cancer Treatment Market Attractiveness Analysis, by Region, 2023–2031
Figure 08: North America Ovarian Cancer Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 09: North America Ovarian Cancer Treatment Market Value Share Analysis, by Treatment, 2022 and 2031
Figure 10: North America Ovarian Cancer Treatment Market Attractiveness Analysis, by Treatment, 2023–2031
Figure 11: North America Ovarian Cancer Treatment Market Value Share Analysis, by End-user, 2022 and 2031
Figure 12: North America Ovarian Cancer Treatment Market Attractiveness Analysis, by End-user, 2023–2031
Figure 13: North America Ovarian Cancer Treatment Market Value Share Analysis, by Country, 2022 and 2031
Figure 14: North America Ovarian Cancer Treatment Market Attractiveness Analysis, by Country, 2023–2031
Figure 15: Europe Ovarian Cancer Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 16: Europe Ovarian Cancer Treatment Market Value Share Analysis, by Treatment, 2022 and 2031
Figure 17: Europe Ovarian Cancer Treatment Market Attractiveness Analysis, by Treatment, 2023–2031
Figure 18: Europe Ovarian Cancer Treatment Market Value Share Analysis, by End-user, 2022 and 2031
Figure 19: Europe Ovarian Cancer Treatment Market Attractiveness Analysis, by End-user, 2023–2031
Figure 20: Europe Ovarian Cancer Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 21: Europe Ovarian Cancer Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 22: Asia Pacific Ovarian Cancer Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 23: Asia Pacific Ovarian Cancer Treatment Market Value Share Analysis, by Treatment, 2022 and 2031
Figure 24: Asia Pacific Ovarian Cancer Treatment Market Attractiveness Analysis, by Treatment, 2023–2031
Figure 25: Asia Pacific Ovarian Cancer Treatment Market Value Share Analysis, by End-user, 2022 and 2031
Figure 26: Asia Pacific Ovarian Cancer Treatment Market Attractiveness Analysis, by End-user, 2023–2031
Figure 27: Asia Pacific Ovarian Cancer Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 28: Asia Pacific Ovarian Cancer Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 29: Latin America Ovarian Cancer Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 30: Latin America Ovarian Cancer Treatment Market Value Share Analysis, by Treatment, 2022 and 2031
Figure 31: Latin America Ovarian Cancer Treatment Market Attractiveness Analysis, by Treatment, 2023–2031
Figure 32: Latin America Ovarian Cancer Treatment Market Value Share Analysis, by End-user, 2022 and 2031
Figure 33: Latin America Ovarian Cancer Treatment Market Attractiveness Analysis, by End-user, 2023–2031
Figure 34: Latin America Ovarian Cancer Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 35: Latin America Ovarian Cancer Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 36: Middle East & Africa Ovarian Cancer Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 37: Middle East & Africa Ovarian Cancer Treatment Market Value Share Analysis, by Treatment, 2022 and 2031
Figure 38: Middle East & Africa Ovarian Cancer Treatment Market Attractiveness Analysis, by Treatment, 2023–2031
Figure 39: Middle East & Africa Ovarian Cancer Treatment Market Value Share Analysis, by End-user, 2022 and 2031
Figure 40: Middle East & Africa Ovarian Cancer Treatment Market Attractiveness Analysis, by End-user, 2023–2031
Figure 41: Middle East & Africa Ovarian Cancer Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 42: Middle East & Africa Ovarian Cancer Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 43: Global Ovarian Cancer Treatment Market Share Analysis, by Company, 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Ovarian Cancer Treatment Market
